Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Notice of Results

Company: Syncona Limited Date: 2024-10-18 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'View Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 National Storage Mechanism | Additional information  ![](https://tracker.live.rns-distribution.com/track.live-rns/5394213_d9353a075fe0b610698e373da828b7e4.png)

RNS Number : 6765I

Syncona Limited

18 October 2024

18 October 2024

Syncona Limited

Notice of Interim Results

Syncona Ltd, ("Syncona" or the "Company") a leading life science investor focused on creating, building and scaling global leaders in life science, will announce its interim results for the period ended 30 September 2024 on Thursday 14 November 2024 .

An in-person presentation for analysts will take place at 09.00am GMT, with a webcast available on the Company's website at [https://www.synconaltd.com/investors/results-and-presentations/](https://www.synconaltd.com/investors/results-and-presentations/) or via this [link](https://sparklive.lseg.com/SynconaLtd/events/e6853198-bdca-4115-af91-fcff433ead69/syncona-interim-results-2024) .

\[ENDS\]

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 20 3981 7912

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com/).  

  

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](https://www.lseg.com/privacy-and-cookie-policy).

END

NORQKOBDOBDDFKD